



Your Collaborative Planning Guide


Industry and Local 338 Welfare and Pension Fund

09/11/14



Historical Performance

Key Metrics by Quarter



Generic Fill Rate % calculated with Unadjusted Rx's



Confidential and Proprietary Information
© 2014 Express Scripts Holding Company. All Rights Reserved.

Plan Performance

- Total Plan Cost is \$688,208, a decrease of 7.9% over the previous period
- Total Gross Cost is \$806,656, a decrease of 8.3% over the previous period
- Total Member Cost is \$118,448, a decrease of 10.2% over the previous period

Plan Performance			
	2013	2012	Change %
AWP	\$1,338,969	\$1,484,111	-9.8%
Network & Mail Discount			
Savings (includes dispensing fees)	-\$532,313	-\$604,693	-12.0%
Tax	\$0	\$0	0.0%
Gross Cost	\$806,656	\$879,418	-8.3%
Member Cost	-\$118,448	-\$131,934	-10.2%
Plan Cost*	\$688,208	\$747,484	-7.9%
Members	1,035	1,237	(16.3%)
Plan Cost PMPM	\$55.42	\$50.37	10.0%

* Financial results have not been audited



Trend Components

- Non-specialty Plan Cost PMPM trend is -0.7% while specialty is at 219.2%
- Inflation is the largest cost driver of your non-specialty Plan Cost PMPM
- Utilization is the largest cost saver of your non-specialty Plan Cost PMPM

	Overall	Non-Specialty	Specialty
Previous Plan Cost PMPM	\$50.37	\$47.90	\$2.47
Utilization	-\$3.36	-\$3.09	\$5.09
Inflation	\$4.45	\$4.12	\$0.29
Drug Mix	\$2.79	-\$0.51	\$0.01
Discount	\$0.96	-\$0.81	-\$0.01
Cost Share	\$0.21	-\$0.06	\$0.02
Change in Plan Cost PMPM	\$5.06	-\$0.35	\$5.41
Current Plan Cost PMPM	\$55.42	\$47.55	\$7.87

Date Range 2013 versus 2012

Utilization based on change in days PMPM

Inflation based on change in AWP/quantity at a drug level

Drug Mix based on changes in therapy, addition of new therapies and the blend of brand/generics

Discount based on change in aggregate AWP discount

Cost share based on change in aggregate member share

- Consider clinical and channel products like step therapy and Exclusive Home Delivery to improve utilization, inflation, drug mix and discount trend components
- Evaluate plan design to ensure appropriate member cost share

Top Line Performance Metrics

- Plan Cost PMPM is \$55.42, a 10.0% trend over the previous period
- Generic Fill Rate (GFR) increased 2.1 percentage points to 77.6%
- Specialty Plan Cost PMPM is \$7.87, a 219.2% trend over the previous period

Teamsters 338			
Description	2013	2012	Change
Avg Subscribers per Month	360	449	-19.8%
Avg Members per Month	1,035	1,237	-16.3%
Number of Unique Patients	747	903	-17.3%
Pct Members Utilizing Benefit	72.2%	73.0%	-0.8
Total Plan Cost	\$688,208	\$747,484	-7.9%
Total Days	290,674	368,536	-21.1%
Total Rx's	7,633	9,558	-20.1%
Average Member Age	33.2	32.9	0.7%
Plan Cost PMPM	\$55.42	\$50.37	10.0%
Plan Cost/Day	\$2.37	\$2.03	16.7%
Plan Cost per Rx	\$90.16	\$78.21	15.3%
Nbr Rx's PMPM	0.61	0.64	-4.6%
Generic Fill Rate	77.6%	75.5%	2.1
Home Delivery Utilization	29.9%	31.7%	-1.8
Member Cost %	14.7%	15.0%	-0.3
Specialty Percent of Plan Cost	14.2%	4.9%	9.3
Specialty Plan Cost PMPM	\$7.87	\$2.47	219.2%
Formulary Compliance Rate	94.9%	94.0%	1.0

Union	
2013	Change
36.9	
\$64.45	1.9%
\$2.56	4.4%
\$96.63	3.0%
0.67	-1.0%
79.4%	2.7
54.8%	-1.1
11.6%	-0.9
19.7%	1.3
\$12.73	9.1%
94.5%	1.0



Key Statistics: Specialty Detailed

- Plan Cost PMPM trend on specialty drugs is 219.2%, compared to a -0.7% Plan Cost PMPM trend on non-specialty drugs
- There are 9 unique specialty patients, an increase of 4 specialty patients over the previous period

Teamsters 338					
Description	Non-Specialty			Specialty	
	2013	2012	Change	2013	2012
Avg Subscribers per Month	360	449	-19.8%	360	449
Avg Members per Month	1,035	1,237	-16.3%	1,035	1,237
Number of Unique Patients	747	903	-17.3%	9	5
Pct Members Utilizing Benefit	72.2%	73.0%	-0.8	0.9%	0.4%
Total Plan Cost	\$590,455	\$710,878	-16.9%	\$97,753	\$36,606
Percent of Total Plan Cost	85.8%	95.1%	-9.3	14.2%	4.9%
Total Days	289,020	367,840	-21.4%	1,654	696
Total Rx's	7,595	9,542	-20.4%	38	16
Percent of Total Rx's	99.50%	99.83%	-0.3	0.50%	0.17%
Plan Cost PMPM	\$47.55	\$47.90	-0.7%	\$7.87	\$2.47
Plan Cost/Day	\$2.04	\$1.93	5.7%	\$59.10	\$52.59
Plan Cost per Rx	\$77.74	\$74.50	4.4%	\$2,572.46	\$2,287.85
Nbr Rx's PMPM	0.61	0.64	-4.9%	0.003	0.001
Generic Fill Rate	78.0%	75.5%	2.5	0.0%	68.8%
Member Cost %	15.3%	15.2%	0.1	10.7%	11.0%

Specialty Union	
2013	Change
\$12.73	9.1%
\$111.75	9.1%
\$4,009.83	9.3%
0.003	-0.2%
14.4%	-1.2
2.0%	0.0

Top 10 Indications

- The largest trend is in Pain And Inflammation, at 144.8%
- The largest negative trend is in Depression, at -15.4%

REPRESENT
68.9%
OF YOUR TOTAL
PLAN COST

Top Indications by Plan Cost														
2013										2012				
Rank	Peer Rank	Indication	Rxs	Patients	Plan Cost	Generic Fill Rate	Plan Cost PMPM	Rank	Rxs	Patients	Generic Fill Rate	Plan Cost PMPM	Plan Cost PMPM	% Change
1	3	INFLAMMATORY CONDITIONS	37	8	\$86,819	8.1%	\$6.99	7	46	7	17.4%	\$2.88	\$2.88	142.6%
2	1	DIABETES	449	52	\$79,716	48.1%	\$6.42	1	533	49	47.5%	\$5.42	\$5.42	18.4%
3	4	HIGH BLOOD PRESS/HEART DISEASE	972	171	\$60,128	84.2%	\$4.84	3	1,168	192	82.8%	\$4.39	\$4.39	10.4%
4	2	HIGH BLOOD CHOLESTEROL	433	108	\$59,015	67.0%	\$4.75	2	585	135	61.9%	\$5.23	\$5.23	-9.1%
5	5	ASTHMA	385	111	\$45,555	35.8%	\$3.67	5	446	138	19.3%	\$3.67	\$3.67	0.0%
6	6	ULCER DISEASE	363	102	\$40,956	68.6%	\$3.30	4	499	136	74.9%	\$3.79	\$3.79	-13.0%
7	9	DEPRESSION	460	88	\$32,942	85.2%	\$2.65	6	584	115	85.4%	\$3.14	\$3.14	-15.4%
8	20	CONTRACEPTIVES	383	70	\$24,394	72.8%	\$1.96	8	550	90	74.4%	\$2.07	\$2.07	-5.2%
9	22	PAIN AND INFLAMMATION	257	122	\$22,872	82.9%	\$1.84	17	324	158	84.6%	\$0.75	\$0.75	144.8%
10	16	INFECTIONS	780	409	\$21,860	98.2%	\$1.76	9	956	509	97.5%	\$1.98	\$1.98	-10.9%
Total Top 10:			4,519		\$474,258	74.4%	\$38.19		5,691		73.2%	\$33.32	\$33.32	14.6%
Differences Between Periods:			-1,172		-\$20,196	1.3%	\$4.88							

Peer = Express Scripts Peer Union' market segment



Top 25 Drugs

- Represent 41.9% of your total Plan Cost and comprise 11 indications
- 4 of your top 25 are specialty drugs

Top Drugs by Plan Cost													
0 TRICE													
2013													
Rank	Peer Rank	Brand Name	Indication	Rxs	Patients	Plan Cost	Plan Cost / PMPM	Rank	Rxs	Patients	Plan Cost / PMPM	% Change	
1	5	ENBREL	INFLAMMATORY CONDITIONS	5	1	\$32,239	\$2.60	24	1	1	\$0.40	550.1%	
2	131	SIMPONI	INFLAMMATORY CONDITIONS	4	1	\$27,212	\$2.19	2	4	1	\$1.61	36.5%	
3	4	CRESTOR	HIGH BLOOD CHOLESTEROL	78	17	\$21,916	\$1.77	3	72	21	\$1.29	37.3%	
4	1	NEXIUM	ULCER DISEASE	59	17	\$20,029	\$1.61	1	81	26	\$2.00	-19.5%	
5	105	ORENCIA	INFLAMMATORY CONDITIONS	7	1	\$19,313	\$1.56						
6	21	HUMALOG	DIABETES	23	6	\$19,026	\$1.53	4	32	6	\$1.23	24.9%	
7	3	COMPOUND	MISC CONDITIONS	9	4	\$15,853	\$1.28	529	4	1	\$0.00	38440.3%	
8	410	XELJANZ	PAIN AND INFLAMMATION	7	1	\$12,819	\$1.03						
9	47	LANTUS	DIABETES	7	3	\$10,112	\$0.81	8	14	3	\$0.73	11.8%	
10	35	MONTELUKAST SODIUM	ASTHMA	88	31	\$8,636	\$0.70	69	27	15	\$0.20	240.1%	
11	6	ADVAIR DISKUS	ASTHMA	28	17	\$8,617	\$0.69	9	38	19	\$0.65	7.3%	
12	51	LEVEMIR FLEXPEN	DIABETES	12	3	\$8,529	\$0.69	10	27	4	\$0.65	6.5%	
13	18	DIOVAN	HIGH BLOOD PRESS/HEART DISEASE	43	8	\$8,287	\$0.67	19	44	11	\$0.45	47.1%	
14	7	CYMBALTA	DEPRESSION	54	6	\$7,969	\$0.64	21	50	7	\$0.44	46.9%	
15	15	ATORVASTATIN CALCIUM	HIGH BLOOD CHOLESTEROL	77	23	\$7,844	\$0.63	5	99	29	\$1.16	-45.5%	
16	85	VENLAFAXINE HCL ER	DEPRESSION	59	10	\$7,381	\$0.59	7	68	12	\$0.91	-35.0%	
17	40	NOVOLOG FLEXPEN	DIABETES	18	1	\$7,163	\$0.58	86	11	1	\$0.16	262.9%	
18	14	CELEBREX	PAIN AND INFLAMMATION	26	7	\$6,878	\$0.55	15	41	11	\$0.52	7.2%	
19	58	FENOFIBRATE	HIGH BLOOD CHOLESTEROL	47	14	\$6,708	\$0.54	115	26	8	\$0.12	357.2%	
20	12	OXYCONTIN	PAIN	20	2	\$5,638	\$0.45	156	5	1	\$0.07	513.8%	
21	139	AZOR	HIGH BLOOD PRESS/HEART DISEASE	19	5	\$5,535	\$0.45	51	18	4	\$0.27	64.6%	
22	10	JANUVIA	DIABETES	14	5	\$5,473	\$0.44	11	26	7	\$0.63	-30.6%	
23	16	SPIRIVA	COPD	18	4	\$5,032	\$0.41	41	17	4	\$0.30	37.3%	
24	173	BYETTA	DIABETES	6	2	\$4,995	\$0.40	16	10	2	\$0.47	-13.5%	
25	19	ZETIA	HIGH BLOOD CHOLESTEROL	17	5	\$4,989	\$0.40	31	20	5	\$0.32	27.1%	
		Total Top 25:		745		\$288,196	\$23.21		735		\$14.56	59.4%	
		Differences Between Periods:		10		\$72,088	\$8.65						

Peer = Express Scripts Peer 'Union' market segment

Top Specialty Indications

- The largest trend is in Inflammatory Conditions, at 216.5%

Top Specialty Indications by Plan Cost														
2 TRUE		2013										2012		
Overall Rank	Peer Rank	Indication	Rxs	Patients	Plan Cost	PMPM	Overall Rank	Rxs	Patients	Plan Cost	PMPM	Plan Cost	PMPM	% Change
1	3	INFLAMMATORY CONDITIONS	16	3	\$78,764	\$6.34	7	5	2	\$29,746	\$2.00			
9	22	PAIN AND INFLAMMATION	7	1	\$12,819	\$1.03	17							
16	7	CANCER	2	1	\$4,276	\$0.34	26							
38	81	WEIGHT LOSS	12	3	\$1,425	\$0.11	52							
11	14	MISC CONDITIONS	1	1	\$471	\$0.04	63							
Total Top 5:			38		\$97,753	\$7.87						\$29,746	\$2.00	292.8%
Differences Between Periods:			33		\$68,008	\$5.87								

Peer = Express Scripts Peer 'Union' market segment



Top 7 Specialty Drugs

- Represent 14.2% of your total Plan Cost and comprise 5 indications

Top Specialty Drugs by Plan Cost													
2013			2012					% Change					
Overall Rank	Peer Rank	Brand Name	Indication	Rxs	Patients	Plan Cost	Plan Cost / Rx	Plan Cost PMPM	Overall Rank	Rxs	Patients	Plan Cost / Rx	Plan Cost PMPM
1	5	ENBREL	INFLAMMATORY CONDITIONS	5	1	\$32,239	\$6,448	\$2.60	24	1	1	\$5,927	\$0.40
2	131	SIMPONI	INFLAMMATORY CONDITIONS	4	1	\$27,212	\$6,803	\$2.19	2	4	1	\$5,955	\$1.61
5	105	ORENCIA	INFLAMMATORY CONDITIONS	7	1	\$19,313	\$2,759	\$1.56					
8	410	XELJANZ	PAIN AND INFLAMMATION	7	1	\$12,819	\$1,831	\$1.03					
32	109	XELODA	CANCER	2	1	\$4,276	\$2,138	\$0.34					
120	1023	QSYMIA	WEIGHT LOSS	12	3	\$1,425	\$119	\$0.11					
233	313	BOTOX	MISC CONDITIONS	1	1	\$471	\$471	\$0.04					
		Total Top 7:		38		\$97,753	\$2,572	\$7.87		5		\$5,949	\$2.00
		Difference Between Periods:		33		\$68,008	-\$3,377	\$5.87					

Peer = Express Scripts Peer 'Union' market segment



Confidential and Proprietary Information
© 2014 Express Scripts Holding Company. All Rights Reserved.



EXPRESS SCRIPTS® 10


Upcoming Patent Expirations

- Implement programs now to realize savings on brand drugs losing patent protection
- For every 1% increase in GFR the plan could save approximately 2.0% of total plan cost

Based on your current utilization
\$126,611
 in brand drugs are losing patent protection by 2018

Top Drugs Scheduled to Lose Patent Protection through 2018					
Drug Name	Indication	Scheduled Release Year	Plan Cost Rank	Plan Cost PMPM	Plan Cost / Rx
CRESTOR	HIGH BLOOD CHOLESTEROL	2016	3	\$1.77	\$280.98
NEXIUM	ULCER DISEASE	2014	4	\$1.61	\$339.48
DIOVAN	HIGH BLOOD PRESS/HEART DISEAS	2014	13	\$0.67	\$192.73
CELEBREX	PAIN AND INFLAMMATION	2015	18	\$0.55	\$264.55
AZOR	HIGH BLOOD PRESS/HEART DISEAS	2016	21	\$0.45	\$291.34
ZETIA	HIGH BLOOD CHOLESTEROL	2016	25	\$0.40	\$293.50
XELODA	CANCER	2014	32	\$0.34	\$2,137.77
ORTHO EVRA	CONTRACEPTIVES	2015	49	\$0.26	\$117.11
MICARDIS	HIGH BLOOD PRESS/HEART DISEAS	2014	55	\$0.26	\$198.24
EPIPEN 2-PAK	ANAPHYLAXIS	2015	56	\$0.25	\$225.18

Spend on Brand Drugs Losing Patent Protection



Savings calculation excludes Specialty drugs

Expiration dates based on current status and may change due to litigation, patent challenges, etc.



Confidential and Proprietary Information
 © 2014 Express Scripts Holding Company. All Rights Reserved.

Generic Fill Rate Opportunity

Every 1% increase in GFR leads
to Plan Cost savings of

2%

Increased GFR this period saved
you


\$35,513

Improve your GFR to maximum
potential of

89.4%

Savings calculations exclude Specialty drugs
GFR and Maximum Potential GFR calculated with Unadjusted Rx's



Generic Fill Rate Potential



Generic Dispensing

- Generic Fill Rate increases will continue to save the plan money year after year
- For every 1% increase in GFR the plan could save approximately 2.0% of total plan cost

Generic Fill Rate by Month



Slide excludes Specialty drugs
Generic Fill Rate calculated with Unadjusted Rx's



Patient Stratification

Patient Care Needs

Well

Smoking Cessation, Allergies, Constipation/Anti-diarrheals, Topical Antifungal / Antibacterial infection treatment

Acute

Colds & Flu, Strep Throat, Ear Infection, Headache, Sprains


Chronic

Heart Disease, Diabetes, Arthritis, High Blood Pressure, High Cholesterol, Dementia, Back Pain

Complex

Multiple Chronic Conditions such as Heart Failure & Diabetes, Cancer, AIDS, Multiple Sclerosis, Metabolic Syndrome

GFR % calculated with Unadjusted Rx's



	Well		Acute		Chronic		Complex		Total
Members	409	193	377	56	1,035				
Members %	39.5%	18.7%	36.4%	5.4%	100.0%				
Plan Cost	\$37,033	\$36,925	\$365,924	\$248,327	\$688,208				
Plan Cost %	5.4%	5.4%	53.2%	36.1%	100.0%				
Member Age (Avg.)	31.8	27.8	43.0	50.0	33.2				
Copay	\$6,552	\$7,999	\$64,623	\$39,273	\$118,448				
Copay/Member	\$16	\$41	\$171	\$701	\$114				
Plan Spend/Member	\$91	\$191	\$971	\$4,434	\$665				
Days of Therapy/Member	39.5	87.7	493.9	1,275.4	280.9				
GFR %	79.3%	81.5%	77.1%	76.8%	77.6%				
Home Delivery Utilization	28.0%	8.8%	33.0%	27.2%	29.9%				

Top Movers

Largest increases in cost between time periods

Curr Rank	Plan Cost Change	Plan Cost Trend	Brand Name	Drug Description	Current Plan Cost	Current Days of Therapy	Current Patients
1	\$26,313	444%	ENBREL	RHEUMATOID ARTHRITIS/PSORIASIS	\$32,239	420	1
5	\$19,313	N/A	ORENCIA	RHEUMATOID ARTHRITIS AGENT	\$19,313	252	1
7	\$15,804	32148%	COMPOUND	MISC CONDITIONS	\$15,853	245	4
8	\$12,819	N/A	XELJANZ	PAIN AND INFLAMMATION	\$12,819	210	1
10	\$5,601	185%	MONTELUKAST SODIUM	ASTHMA	\$8,636	4,320	31
19	\$4,955	283%	FENOFIBRATE	HIGH CHOLESTEROL	\$6,708	2,250	14
17	\$4,804	204%	NOVOLOG FLEXPEN	DIABETES	\$7,163	387	1
20	\$4,540	414%	OXYCONTIN	NARCOTIC PAIN RELIEF	\$5,638	580	2
32	\$4,276	N/A	XELODA	CANCER AGENT	\$4,276	42	1
2	\$3,393	14%	SIMPONI	RHEUMATOID ARTHRITIS/PSORIASIS	\$27,212	336	1

Drugs in the Top 25 Drugs

Largest decreases in cost between time periods

Curr Rank	Plan Cost Change	Plan Cost Trend	Brand Name	Drug Description	Current Plan Cost	Current Days of Therapy	Current Patients
163	-\$13,003	-94%	SINGULAIR	ASTHMA/ALLERGY	\$768	180	1
4	-\$9,722	-33%	NEXIUM	GASTROESOPHAGEAL REFLUX DISEASE/ULCER THERAPY	\$20,029	3,330	17
15	-\$9,345	-54%	ATORVASTATIN CALCIUM	HIGH CHOLESTEROL	\$7,844	5,910	23
N/A	-\$7,938	N/A	TRICOR	HIGH CHOLESTEROL	N/A	N/A	N/A
N/A	-\$6,860	N/A	ENOXAPARIN SODIUM	DVT/ANTICOAGULATION	N/A	N/A	N/A
16	-\$6,188	-46%	VENLAFAXINE HCL ER	ANTIDEPRESSANT AGENT	\$7,381	2,118	10
108	-\$6,110	-79%	ABILIFY	ANTIPSYCHOTIC AGENT	\$1,650	60	1
105	-\$6,012	-78%	SUBOXONE	OPIOID DEPENDENCE	\$1,684	139	2
185	-\$4,596	-87%	PENTASA	GASTROINTESTINAL AGENT	\$661	30	1
N/A	-\$4,554	N/A	MONODOX	ANTIBIOTIC	N/A	N/A	N/A

Drugs in the Top 25 Drugs




Condition-Specific Specialized Pharmacy Model

Focuses on those who need care most

Pharmacists closing gaps in care

- Adherence
- Lower cost drug
- Lower cost channel



Specialized Pharmacy Practice via Therapeutic Resource Centers SM									
Rare and Specialty	Oncology	HIV/Immunology	Diabetes	Cardiovascular	Pulmonary	Neuroscience	Women's Health		
3 Patients	6 Patients	10 Patients	43 Patients	118 Patients	118 Patients	142 Patients	42 Patients		
0.0% Retail	50.0% Retail	80.0% Retail	65.1% Retail	60.2% Retail	85.6% Retail	93.0% Retail	95.2% Retail		
Only Patients	Only Patients	Only Patients	Only Patients	Only Patients	Only Patients	Only Patients	Only Patients		
\$64,039 Plan Cost	\$27,393 Plan Cost	\$30,970 Plan Cost	\$138,278 Plan Cost	\$160,570 Plan Cost	\$94,654 Plan Cost	\$91,711 Plan Cost	\$21,130 Plan Cost		
9.3% Plan Cost	4.0% Plan Cost	4.5% Plan Cost	20.1% Plan Cost	23.3% Plan Cost	13.8% Plan Cost	13.3% Plan Cost	3.1% Plan Cost		



Key Statistics: Detailed

Teamsters 338			
	2013	2012	Change
Demographics			
Avg Subscribers per Month	360	449	-19.8%
Avg Members per Month	1,035	1,237	-16.3%
Average Member Age	33.2	32.9	0.7%
Cost			
Total AWP	\$1,338,969	\$1,484,111	-9.8%
Total Gross Cost	\$806,656	\$879,418	-8.3%
Total Member Cost	\$118,448	\$131,934	-10.2%
Total Plan Cost	\$688,208	\$747,484	-7.9%
Gross Cost PMPM	\$64.96	\$59.26	9.6%
Plan Cost PMPM	\$55.42	\$50.37	10.0%
AWP per Days of Therapy	\$4.61	\$4.03	14.4%
Gross Cost per Days of Therapy	\$2.78	\$2.39	16.3%
Plan Cost per Days of Therapy	\$2.37	\$2.03	16.7%
Copay per Rx	\$15.52	\$13.80	12.4%
Member Cost %	14.7%	15.0%	-0.3
Specialty Plan Cost PMPM	\$7.87	\$2.47	219.2%
Specialty Percent of Plan Cost	14.2%	4.9%	9.3
Utilization			
Total Rxs	7,633	9,558	-20.1%
Nbr Rxs PMPM	0.61	0.64	-4.6%
Number of Unique Patients	747	903	-17.3%
Pct Members Utilizing Benefit	72.2%	73.0%	-0.8
Days of Therapy per Member	280.9	298.0	-5.7%
Days of Therapy per Subscriber	807.8	821.6	-1.7%
Home Delivery Utilization	29.9%	31.7%	-1.8
Generic Fill Rate	77.6%	75.5%	2.1
Generic Conversion Rate	98.3%	97.6%	0.7
Formulary Compliance Rate	94.9%	94.0%	1.0

Union	
2013	Change
N/A	N/A
N/A	N/A
36.9	0.0%
N/A	N/A
N/A	N/A
N/A	N/A
\$72.91	0.9%
\$64.45	1.9%
N/A	N/A
\$2.90	3.4%
\$2.56	4.4%
\$12.19	-5.5%
11.6%	-0.9
\$12.73	9.1%
19.7%	1.3
N/A	N/A
0.67	-1.0%
N/A	N/A
N/A	N/A
301.5	-2.4%
701.9	-2.7%
54.8%	-1.1
79.4%	2.7
N/A	N/A
94.5%	1.0



